NIH Study Sections

In an article entitled "Clinicians Catch Top NIH Officials' Attention" (E. Marshall, Science, 267:448, 1995), Roy Silverstein of the New York University Medical Center said that he is convinced that "patient-oriented research is being underfunded because of some inherent flaws in the review process" at the National Institutes of Health. Alternatively, in a recent piece entitled "How Federal Funding Mechanisms Stifle Basic Biomedical Research" (The Scientist, Aug. 21, 1995, page 10), Edith Ros

Written byPaul Strudler
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Alternatively, in a recent piece entitled "How Federal Funding Mechanisms Stifle Basic Biomedical Research" (The Scientist, Aug. 21, 1995, page 10), Edith Rosenberg of the Howard University School of Medicine expresses the belief that it is "basic science" that is being poorly reviewed and that "applied science, which requires the collaboration of many diverse people with their support staff and specialized instruments, has generally received the lion's share of research funds distributed by NIH."

In another piece in the same August 21 issue of The Scientist, titled "NIH Study Section Members Acknowledge Major Flaws In The Reviewing System" [R. Finn, page 1], Howard Schachman, ombudsman to the NIH director, is quoted as saying, "There's one group of people who will say: 'I never heard of those reviewers, they're a bunch of young kids,' and another group that will say: 'Look, it's the old boy's network; no wonder I didn't get ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies